Artios Pharma, a Babraham-based biopharma company realising the therapeutic power of targeting the DNA damage response in ...
Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...
Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...
Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...
Artificial intelligence (AI) is set to transform the care of women with cancer. From early detection via digital phenotyping ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.
Today’s Google Doodle for the India region shows the base of generic codes - DNA or Deoxyribonucleic Acid. On the purpose of ...
Googles DNA Doodle explains the molecule of life Read ahead to know science surprising fun facts and memory hacks behind your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback